Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306868 | 1.00 | HCRTR1 (0.55) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL10045468 | 0.91 | HCRTR1 (0.57) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL20306858 | 0.87 | HCRTR1 (0.52) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL20306856 | 0.87 | HCRTR1 (0.52) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL10072235 | 0.87 | HCRTR1 (0.52) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL10072236 | 0.87 | HCRTR1 (0.53) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL20306867 | 0.87 | HCRTR1 (0.53) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL10072239 | 0.86 | OPRM1 (0.56) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL20306866 | 0.86 | OPRM1 (0.56) | HCRTR1OPRM1OPRD1OPRK1 | |
| SCHEMBL20306862 | 0.86 | OPRM1 (0.56) | HCRTR1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005790-B2 | Process for the synthesis of substituted morphinans | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-06-26 | — | — | US | disclosed |
| US-20140303371-A1 | Process for the Synthesis of Substituted Morphinans | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| US-20120010412-A1 | Process for the Synthesis of Substituted Morphinans | ALKERMES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2012005795-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED MORPHINANS | ALKERMES, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303371-A1 | Process for the Synthesis of Substituted Morphinans | CYP1B1, DHPS, CYP4B1 | HCRTR1 3605/4885OPRM1 251/4885OPRD1 1176/4885 |
| US-20120010412-A1 | Process for the Synthesis of Substituted Morphinans | CYP1B1, DHPS, CYP4B1 | HCRTR1 3605/4885OPRM1 251/4885OPRD1 1176/4885 |
| US-10005790-B2 | Process for the synthesis of substituted morphinans | CYP1B1, CYP2F1, CYP1A2 | HCRTR1 1435/4885OPRM1 72/4885OPRD1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.